Kavak is a global company with operations in Mexico, Argentina, Brazil, Chile, Turkey, Saudi Arabia, Oman and United Arab Emirates. We are the number one e-commerce company in the purchase and sale of pre-owned vehicles and the most highly valued private startup in Latin America. Kavak is also the first Unicorn Company in the history of Mexico, with a current valuation of US$8.7 billion. We have thousands of kavak@s from more than 40 different nationalities and growing. As part of this accelerated growth, we want to make sure we surround ourselves with the best talent to help us continue to build the technology, processes and products that will allow us to transform the automotive market around the world. Our team is the number one priority. We like to imagine the impossible and work together to achieve it. We are disruptive, proactive, loyal and ambitious. Interested in joining? Apply now.
With 20+ years of collective experience, OeP helps brands capitalize on Amazons growth, using data-driven strategies executed by experts, enabled by technology, and aligned with Amazons dynamic platform and KPIs.
About Kotak Mahindra Group: Established in 1985, the Kotak Mahindra Group is one of Indias leading financial services conglomerates. In February 2003, Kotak Mahindra Finance Ltd. (KMFL), the Groups flagship company, received a banking license from the Reserve Bank of India (RBI). With this, KMFL became the first non-banking finance company in India to become a bank – Kotak Mahindra Bank Limited. The consolidated balance sheet of Kotak Mahindra Group is over 1 lakh crore and the consolidated net worth of the Group stands at 13,943 crore (approx US$ 2.6 billion) as on September 30, 2012. The Group offers a wide range of financial services that encompass every sphere of life. From commercial banking, to stock broking, mutual funds, life insurance and investment banking, the Group caters to the diverse financial needs of individuals and the corporate sector. The Group has a wide distribution network through branches and franchisees across India, and international offices in London, New York, California, Dubai, Abu Dhabi, Bahrain, Mauritius and Singapore. For more information, please visit the companys website at http://www.kotak.com
Selena Group is a leading global manufacturer of construction chemicals and polyurethane foam, established in 1992 and based in Wrocław, Poland. The company operates in 18–19 countries with around 1,800–2,000 employees and has 30–35 subsidiaries, including manufacturing facilities in Poland, South Korea, China, Romania, Turkey, Spain, Kazakhstan, and Italy. Selena Group is recognized as one of the top four manufacturers of assembly foam and a significant distributor of construction chemicals. Its product range includes high-yield polyurethane foams, sealants, adhesives, waterproofing systems, and thermal insulation solutions. The company operates through four specialized divisions: Interior & Decorations, Windows & Doors, Waterproofing, and Walls, Facades & Chemical Constructions. Selena serves 100 markets worldwide, focusing on professional contractors, industrial users, and home builders, while emphasizing sustainability and innovation in its offerings.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.